MedTrace Logo

Early Outcome of Mechanochemical Endovenous Ablation

NCT01459263 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 124

Last updated 2018-04-26

No results posted yet for this study

Summary

More than 25 percent of the general population suffers from varicose veins, which has a considerable impact on quality of life. Nowadays endovenous treatment modalities for great saphenous incompetence are widely accepted. Mechanochemical endovenous ablation is a new tumescent-less technique, that combines mechanical endothelial damage using a rotating wire with the infusion of a liquid sclerosant. The current study aims at evaluating short and long term outcome after mechanochemical endovenous ablation.

Conditions

  • Varicosis

Interventions

DEVICE

ClariVein

Using the ClariVein device, the GSV will be occluded.

Sponsors & Collaborators

  • St. Antonius Hospital

    collaborator OTHER

  • Rijnstate Hospital

    lead OTHER

Principal Investigators

  • Michel MJ Reijnen, MD, PhD · Rijnstate Hospital

  • Jean-Paul Vries, de, MD, Phd · St. Antonius Hospital

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2018-02-28
Completion
2018-02-28

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01459263 on ClinicalTrials.gov